Unraveling Rising Mortality: Statistical Insights from Japan and International Comparisons.

Publication date: May 30, 2025

Since the onset of the COVID-19 pandemic, Japan has experienced a significant rise in mortality, with excess deaths surpassing historical projections. Statistical data indicate a sharp increase in mortality rates from 2021 onward, attributed to COVID-19, aging demographics, cardiovascular diseases, and malignancies. Preliminary 2024 data suggest continued excess mortality, fueling public debate. This review analyzes national and municipal mortality trends using official Japanese statistics and comparative data from South Korea, the U. S., and the EU. Findings reveal a sharp mortality rise post-2021 in Japan and South Korea, while Western nations experienced peak deaths in 2020, followed by declines. The review explores contributing factors, including potential vaccine-related adverse effects, declining healthcare access, pandemic-induced stress, and demographic shifts. Notably, older adults’ reluctance to seek medical care led to delayed diagnoses, treatment interruptions, and preventable deaths. Although some argue that declining COVID-19 vaccination rates in 2023 may have contributed to rising mortality in 2024, available data suggest a multifactorial causation. Japan’s rapidly aging population, coupled with increasing mortality and declining birth rates, presents profound social and economic challenges. A nuanced approach, avoiding simplistic causal claims, is crucial for understanding these trends. This review highlights the need for a sustainable societal framework to address demographic shifts and improve healthcare resilience. Future pandemic strategies must balance infection control measures with mitigating unintended health consequences to ensure a more adaptive and effective public health response.

Open Access PDF

Concepts Keywords
Basel COVID-19 pandemic
Japanese declining population
Pandemic demographic shifts
Vaccination healthcare system
mortality

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH cardiovascular diseases
disease MESH malignancies
drug DRUGBANK Isoxaflutole
disease MESH infection
drug DRUGBANK Troleandomycin
drug DRUGBANK Coenzyme M
disease MESH myocarditis
disease MESH autoimmune diseases
disease MESH death
disease IDO country
disease IDO immune response
disease MESH breakthrough infections
disease MESH sequelae
disease MESH heart failure
disease MESH arrhythmia
disease MESH cardiac arrest
disease MESH pulmonary embolism
disease MESH syndrome
disease MESH lifestyle
disease MESH obesity
drug DRUGBANK Coagulation factor X human
disease MESH illusion
drug DRUGBANK BCG vaccine
disease IDO cell
disease IDO susceptibility
disease MESH infectious diseases
disease MESH cytopenia
disease MESH nephrosis
disease MESH nephritis
disease MESH pericarditis
disease IDO role
drug DRUGBANK Nonoxynol-9
disease IDO intervention
disease MESH cerebrovascular diseases
disease MESH dementia
disease MESH dental diseases
disease MESH emergency
disease MESH anxiety
disease MESH STEMI
disease MESH heart attack
disease MESH acute ischemic stroke
disease MESH stroke
disease MESH frailty
disease MESH chronic diseases
disease MESH sarcopenia
disease MESH cognitive decline
disease MESH osteonecrosis
disease MESH psychological stress
disease MESH uncertainty
disease MESH psychological distress
disease MESH post traumatic stress disorder
drug DRUGBANK Etoperidone
disease MESH non communicable diseases
disease MESH leukemia
drug DRUGBANK Methylergometrine
disease IDO quality
drug DRUGBANK Methionine
disease MESH social stigma
disease IDO protein
disease MESH suicide
disease MESH shock
disease IDO history
disease IDO site
disease IDO symptom
disease IDO host
disease MESH Long COVID
drug DRUGBANK Delorazepam
drug DRUGBANK Bismuth subgallate
disease MESH herpes zoster
disease MESH rheumatic diseases
disease MESH ANCA Associated Vasculitis
disease MESH thrombocytopenia
disease MESH Membranous Nephropathy
drug DRUGBANK Carboxyamidotriazole
disease MESH glomerulonephritis
disease MESH acute tubulointerstitial nephritis
disease MESH IgA nephropathy
disease MESH membranoproliferative glomerulonephritis
disease MESH Inflammation

Original Article

(Visited 1 times, 1 visits today)